Piper Jaffray Initiates Coverage on Valeant Pharmaceuticals (VRX) with an Underweight; Valuation Based on Sum-of-the-Parts
Tweet Send to a Friend
Piper Jaffray & Co. initiates coverage on Valeant Pharmaceuticals (NYSE: VRX) with an Underweight. Price target $18.
Piper analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Piper analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
